Trade Medivir B - MEDIVIR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.08 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.019778% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.002445% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | SEK | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | Sweden | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.76 |
| Open | 2.76 |
| 1-Year Change | -58.56% |
| Day's Range | 2.72 - 2.76 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 8, 2024 | 2.74 | -0.02 | -0.72% | 2.76 | 2.78 | 2.70 |
| Nov 7, 2024 | 2.76 | 0.00 | 0.00% | 2.76 | 2.82 | 2.66 |
| Oct 31, 2024 | 2.82 | 0.06 | 2.17% | 2.76 | 2.82 | 2.76 |
| Oct 30, 2024 | 2.76 | -0.04 | -1.43% | 2.80 | 2.80 | 2.76 |
| Oct 29, 2024 | 2.82 | -0.02 | -0.70% | 2.84 | 2.88 | 2.78 |
| Oct 28, 2024 | 2.90 | 0.02 | 0.69% | 2.88 | 2.92 | 2.88 |
| Oct 25, 2024 | 2.76 | 0.00 | 0.00% | 2.76 | 2.76 | 2.72 |
| Oct 24, 2024 | 2.76 | 0.00 | 0.00% | 2.76 | 2.76 | 2.70 |
| Oct 23, 2024 | 2.68 | -0.02 | -0.74% | 2.70 | 2.70 | 2.66 |
| Oct 22, 2024 | 2.68 | -0.02 | -0.74% | 2.70 | 2.70 | 2.60 |
| Oct 21, 2024 | 2.72 | 0.00 | 0.00% | 2.72 | 2.72 | 2.70 |
| Oct 18, 2024 | 2.74 | -0.04 | -1.44% | 2.78 | 2.78 | 2.74 |
| Oct 17, 2024 | 2.72 | -0.04 | -1.45% | 2.76 | 2.82 | 2.72 |
| Oct 16, 2024 | 2.82 | 0.04 | 1.44% | 2.78 | 2.84 | 2.78 |
| Oct 15, 2024 | 2.76 | 0.04 | 1.47% | 2.72 | 2.80 | 2.72 |
| Oct 14, 2024 | 2.72 | 0.00 | 0.00% | 2.72 | 2.72 | 2.72 |
| Oct 11, 2024 | 2.82 | 0.00 | 0.00% | 2.82 | 2.86 | 2.82 |
| Oct 10, 2024 | 2.88 | 0.04 | 1.41% | 2.84 | 2.90 | 2.82 |
| Oct 9, 2024 | 2.88 | 0.04 | 1.41% | 2.84 | 2.88 | 2.82 |
| Oct 8, 2024 | 2.82 | 0.00 | 0.00% | 2.82 | 2.82 | 2.82 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Medivir Company profile
About Medivir AB
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Medivir AB revenues increased 83% to SEK25.5M. Net loss increased 48% to SEK63.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -SEK1.44 to -SEK1.19.
Equity composition
01/2007, Rigths Issue, 3 new shares for every 5 shares held @ SEK 29 (Factor: 1.224545). 04/2010, Rights Issue, 1 new share for every 4 shares held @ SEK 62 (Factor: 1.10266). 2/2015, complex stock split (Factor: 1.59182) 1/2021, Rights Issue, 1 new share for every 1 share held @ SEK7 (Factor: 1.21788).
| Industry: | Bio Therapeutic Drugs |
Lunastigen 5, 2 tr
HUDDINGE
STOCKHOLM 141 22
SE
News
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com